// App-Quantinova.ai

DXT26 : Long-Term Disease Stability Assessed By the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the Clarity and Clarity Extension Studies

Researchers

Presenter

  • Gavin Giovannoni

Principal Investigators

  • Giancarlo Comi

  • Kottil Rammohan

  • Peter Rieckmann

  • Patrick Vermersch

  • Fernando Dangond

  • Birgit Keller

  • Dominic Jack

Medical Centers

  • university of louisville

  • Multiple Sclerosis Center, University of Miami, Miami, FL

  • Medical Park Loipl, and University of Erlangen

  • Queen Mary University, London, UK

  • Università Vita-Salute San Raffaele

Locations

  • United Kingdom

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Genetic Disorder

Disease

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved